Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Up 317.8% in October

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 6,605 shares, an increase of 317.8% from the September 30th total of 1,581 shares. Based on an average daily trading volume, of 41,123 shares, the days-to-cover ratio is currently 0.2 days. Currently, 1.0% of the shares of the company are short sold.

Revelation Biosciences Stock Performance

NASDAQ REVB traded down $0.05 during trading hours on Wednesday, reaching $3.68. The company’s stock had a trading volume of 9,007 shares, compared to its average volume of 34,501. The stock has a market cap of $2.51 million, a PE ratio of -0.04 and a beta of -0.07. The company’s 50-day moving average is $6.00 and its two-hundred day moving average is $8.65. Revelation Biosciences has a fifty-two week low of $3.08 and a fifty-two week high of $40.60.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($6.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.12) by $0.03. Equities analysts expect that Revelation Biosciences will post -36.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday, October 14th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Revelation Biosciences has a consensus rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.